Advancing small molecule programs from drug substance development through drug product manufacturing requires more than strong science. Success depends on integrated strategies that connect process development, scale-up, manufacturing, and formulation innovation to support quality, efficiency, and long-term commercial readiness.
Organizations must balance evolving technical, operational, and regulatory demands while optimizing both active pharmaceutical ingredient (API) production and finished dosage form development. From enhancing manufacturing performance and supply chain resilience to implementing innovative drug product technologies, aligning these capabilities can help accelerate timelines, reduce risk, and support successful product launches.
Discover practical approaches for strengthening drug substance and drug product development in this edition of the Outsourced Pharma Capabilities Update. Watch the presentations below to gain valuable insights for your next manufacturing, formulation, and commercialization initiative.
Recent Sessions Available On-Demand
Navigating The Complexities Of ADC Development And Manufacturing – October 2026
Turning Fill/Finish Complexity Into Commercial Readiness – October 2026
mRNA Manufacturing And Packaging Strategies – October 2026
Advancing the Future Of Drug Development – October 2026
Upcoming OPCU Topics & Times
Enabling ADC Success | 12/1/2026, PM Session
Mastering Aseptic Fill-Finish | 12/1/2026, PM Session
Access more on-demand OPCU recordings and upcoming sessions here.